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Maleimide-functionalised Pt(IV) complexes with highly 
selective binding properties to thiol groups were synthesised 
as precursors for binding of thiol-containing tumour 10 
targeting molecules like human serum albumin. 
The use of metal-based drugs in cancer therapy is well 
established due to the worldwide success of the platinum(II) 
drugs cisplatin, carboplatin and oxaliplatin.1,2 Nevertheless, 
therapy with these compounds is characterised by severe adverse 15 
effects as a result of the unselective damage to healthy tissues and 
acquired or intrinsic resistance.3 One approach to overcome the 
drawbacks of platinum(II) chemotherapeutics is the development 
of platinum(IV) complexes. This class of compounds is 
kinetically more inert and it is widely accepted that they act as 20 
prodrugs. Thus, platinum(IV) complexes open up the possibility 
to develop platinum drugs with reduced toxicity and enable 
potential oral application. The most prominent platinum(IV) drug 
is satraplatin which is currently investigated in advanced phase 
III clinical trials. 2,4 The additional axial ligands of platinum(IV) 25 
complexes allow the coupling of bioactive molecules like 
estrogen,5 ethacrynic acid,6 folic acid,7 carbon nanotubes8 or gold 
nanoparticles.9 
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Fig 1. The concept of maleimide-functionalised platinum(IV) prodrugs. 
 
These moieties are then released during the so called “activation 50 
by reduction” process accompanied by simultaneous generation 
of the corresponding reactive platinum(II) drugs.  
However, there is increasing evidence that also platinum(IV) 
compounds are not specifically activated only in the tumour 
tissue but also in healthy tissues, especially in the presence of 55 
hemeproteins.10-12 Thus, it is of interest to further enhance the 
tumour-targeting of platinum(IV) drugs.  
A well-known targeting molecule is albumin, the most abundant 
protein in human blood serum which accumulates in the tumour 
tissues, due to the EPR (“enhanced permeability and retention”) 60 
effect.13 In addition, human serum albumin (HSA) possesses a 
single free thiol group (cysteine-34), which enables the selective 
and defined preparation of drug-HSA conjugates using maleimide 
as the coupling moiety. The favourable properties of HSA-
coupled anticancer drugs were already clinically proven for 65 
doxorubicin (INNO206; aldoxorubicin), currently in phase II 
clinical studies,14 and a HSA-based nanoparticle encapsulating 
paclitaxel (Abraxane®) approved for the treatment of breast 
cancer and non-small cell lung cancer (NSCLC).15 
Herein, we report on the synthesis of the first platinum(IV) 70 
complexes containing a maleimide moiety in axial position, 
which enables a simple and fast coupling of thiol-containing 
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Scheme 1. Synthesis of novel platinum(IV) complexes (a: NN  = 1,2-
ethylenediamine, Y = Cl; b: NN = 1R,2R-diaminocyclohexane, Y2 = 
oxalate) 
Fig 2. ORTEP plot of 3a with atom labelling scheme, the thermal 5 
ellipsoids have been drawn at 50% probability level. 
 
targeting molecules. This was confirmed by investigations with 
cysteine and HSA. 
The starting compounds 1a and 1b were synthesised by standard 10 
literature procedures, followed by oxidation with H2O2 (2a and 
2b, Scheme 1).16 The maleimide-containing linker was generated 
by conversion of maleimidopropanoic acid to the isocyanate, 
which was subsequently coupled to the platinum centre by 
reaction with the hydroxido groups of the corresponding 15 
platinum(IV) precursor in DMF yielding 3a (67%) and 3b (44%). 
As a reference complex, which is unreactive towards thiols, the 
succinimide functionalised compound 4b was synthesised by an 
analogous procedure in good yields (53%). All complexes were 
characterised by one- and two-dimensional NMR spectroscopy, 20 
ESI-mass spectrometry and elemental analysis (see SI). 
The results of an X-ray crystallographic study of § 3a are shown 
in Fig. 2. The complex crystallised in the monoclinic space group 
C2/c, with octahedral coordination geometry. In the equatorial 
plane the bidentate ethane-1,2-diamine and two chlorido ligands 25 
are coordinated to the platinum(IV) core, whereas in the axial 
position the two 2-maleimideethylcarbamoyl moieties are bound. 
The bond lengths are in good accordance with comparable 
compounds in literature,16,17 with Pt–Cl at around 2.3 Å and both 
Pt–O and Pt–N close to 2.0 Å (for bond lengths and angles see 30 
Tables S1, S2, SI). 
The stability of the novel complexes in aqueous solution was 
measured with RP-HPLC over a period of 24 h. For both 
maleimide derivatives 3a and 3b slow hydrolysis could be  
Fig 3. Binding studies of 3b with albumin using RP-HPLC. 35 
 
observed (<1%/h, Fig. S1, SI). In comparison, the recorded 
chromatograms of the succinimide derivative 4b showed no 
change within 24 h suggesting that the changes in the case of 3a 
and 3b originate from slow hydrolysis of the maleimide moiety. 40 
Subsequently, the complexes were incubated with an excess of 
cysteine to analyse the reactivity of the thiol group with the 
maleimide moiety (Fig. S2, SI). The results showed an immediate 
and complete reaction of cysteine with complexes 3a and 3b (<2 
min). In contrast, the succinimide derivative 4b showed no 45 
reaction during the same time (1.5 h, Fig. S3, SI), which proves 
the selective binding of cysteine to the maleimide moiety without 
any reaction with the platinum centre. The binding rate of 3a and 
3b to HSA was measured in aqueous solution in 4:1 albumin-to-
Pt ratio. The analyses indicated a rapid albumin linkage with a 50 
half-time of ~1 h for both maleimide complexes (Fig. 3). To 
further investigate the albumin binding in detail, 3a, 3b, and 4b 
where incubated with HSA for 4 h at various concentrations in 
phosphate buffer, followed by addition of an excess 2,2’-
dithiodipyridine which reacts with the remaining free thiol groups 55 
of cysteine-34 and results in the generation of 2-thiopyridone, 
which can be quantified by UV-vis spectroscopy (see SI). In the 
case of 4b, the thiol groups of HSA remain unreacted at all tested 
concentrations, whereas an exponential decrease of free SH was 
found for the maleimide-containing complexes 3a and 3b (Fig. 60 
4). 
This data reveals that around 80% of the maleimide-containing 
platinum(IV) compound is bound to HSA after 4 h incubation at a 
concentration of >30 µM. The original concentration of free SH 
groups from HSA was ~25 µM (see SI) and a binding-saturation 65 
Fig 4. Free SH-content of HSA at various platinum complex/HSA ratios 
after 4 h incubation, 3a (○), 3b (▲), 4b (□) [cHSA = 99.2 µM; pH = 7.40, 
20 mM phosphate puffer + 0.10 M NaCl, 2% (m/m) DMSO]. 
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was reached at ca. 25–30 µM of the Pt-complex, which suggests a 
1:1 Pt-HSA adduct possibly due to steric hindrance of the second 
maleimide group.  
To investigate the drug protein binding properties of 3b in fetal 
calf serum (FCS), SEC-ICP-MS measurements of sulphur and 5 
platinum were performed (Fig 5). The majority (>70%) of 
platinum was detected in the frame of 8–9 min, which 
corresponds to the retention time of albumin (see SI). Only small 
amounts of 3b were found in the low molecular weight fraction, 
while 4b was exclusively detected in this fraction. 10 
To test the impact of albumin binding on the anticancer activity 
of the new compounds in vivo the murine CT-26 colon cancer 
model was used. The use of this syngeneic murine tumour model 
was necessary due to the recently reported importance of the 
immune system for the anticancer activity of oxaliplatin.10 Both 15 
platinum complexes are well tolerated with no significant loss of 
body weight (data not shown). As depicted in Fig. 6, both drugs 
had potent anticancer potential resulting in significantly reduced 
tumour growth in case of 4b and even disease stabilisation in case 
of the maleimide-containing 3b. Thus, 3b had a significantly 20 
higher anticancer activity (p <0.01 at day 15) against CT-26 
Fig 5. Size-exclusion chromatography (SEC-)ICP-MS determination of 
3b (50 µM) in fetal calf serum after 2h of incubation. 
Fig 6. In vivo anticancer activity. CT-26 cells were injected 
subcutaneously in the right flank of BALB/c mice. Mice were treated on 25 
day 5, 8, and 12 (indicated by ▼) i.v. with 18 mg/kg 3b and 4b. Tumour 
volumes were calculated as described in the Supporting Information. Each 
experimental group contained four animals. Data are means ± SEM 
Statistical analysis was performed by two-way ANOVA with Bonferroni 
post-test (*, p <0.05; **, p <0.01; ***, p <0.001 compared to control 30 
mice).  
tumours than 4b resulting in a distinctly lower mean tumour 
burden (of 0.38 g vs. 0.18 g for 4b and 3b, respectively at day 
15). Together, this suggests that the albumin binding of 3b leads 
either to prolonged plasma half-life of the drug and/or a more 35 
selective accumulation in the malignant tissue due to the EPR 
effect.  
Based on our data it seems feasible that the combination of 
maleimide-mediated platinum(IV) binding to serum albumin 
together with the “activation by reduction” principle can be used 40 
to enhance the tumour-targeting of platinum drugs. 
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